Doptelet

Shares of small-cap biotech Dova Pharmaceuticals Inc (NASDAQ: DOVA) were advancing strongly Monday in reaction to a buyout deal. Deal Terms Dova said Monday it has entered into an agreement to be bought by Swedish Orphan Biovitrum, or SOBI, for $27.50 per share in cash, along with one non-...

Shares of thinly traded small-cap biotech Dova Pharmaceuticals Inc (NASDAQ: DOVA) were solidly higher Thursday, adding to the gains they notched early in the week . Dova announced Tuesday that its Doptelet was granted marketing authorization in Europe for treating severe...

The FDA approval machinery worked overtime in May, with several new labelings, original approvals and new molecule approvals coming through in the month. The month saw the approval of two new molecular entities, or NMEs: Novartis AG (NYSE: NVS)'s Piqray in combination with fulvestrant to treat...

Raymond James launched coverage of two pharmaceutical names Tuesday afternoon with bullish ratings. Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) is a clinical-stage biopharmaceutical company that addresses key mechanisms of tumor drug resistance. Dova Pharmaceuticals Inc (NASDAQ: DOVA)...